Vertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story

Vertex Pharmaceuticals and CRISPR Therapeutics are initiating patient treatments with their gene-editing therapy, Casgevy, approved for sickle cell disease and beta thalassemia. This rollout is critical for Vertex as it aims to diversify beyond its cystic fibrosis focus, with Casgevy expected to contribute to a projected US$500 million in non-CF product revenue for 2026. Investors will closely monitor the real-world adoption, patient access, and payer response to this high-complexity treatment, as these factors will shape Vertex’s future earnings and its position in the broader gene-editing market.